Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure

Weerawat Manosuthi1*, Supeda Thongyen1, Samruay Nilkamhang1, Sukanya Manosuthi1 and Somnuek Sungkanuparph2

Abstract

Background: We continue the previously described prospective cohort study of ritonavir-boosted lopinavir (LPV/r) monotherapy for second-line therapy in HIV-infected patients with prior failure and extensive resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), with the objective being to determine the three-year treatment responses.

Findings: There were 40 patients with a mean ± SD age of 37 ± 8 years. Median (IQR) baseline CD4 was 123 (37-245) cells/mm³ and median (IQR) HIV-1 RNA was 55,800 (9,670-100,000) copies/mL. All patients received twice daily LPV/r 400/100 mg and recycled lamivudine 150 mg. By intend-to-treat analysis at 144 weeks, 26 (65%) and 22 (56%) patients achieved HIV-1 RNA at < 400 and < 50 copies/mL, respectively. In as-treated analysis, the corresponding rates were 26 of 28 (93%) and 22 of 28 (78%), respectively. Low-level viral rebound (HIV-1 RNA 50-400 copies/mL) was found in 6 (15%), 6 (15%), and 4 (10%) patients at week 48, 96, and week 144, respectively. Medians CD4 at week 48, 96, and 144 were 351, 481, and 584 cells/mm³ and significantly changed from baseline (all, \( P < 0.05 \)). There were increments of mean triglycerides at 48 weeks and 144 weeks from baseline (\( P < 0.05 \)). No major protease resistance-associated mutations emerged after virologic failure.

Conclusion: LPV/r monotherapy with recycled lamivudine can maintain long-term virologic suppression in a relatively small proportion of patients failing NNRTI-based regimen and having limit option for active NRTI. More antiretroviral classes are needed be accessible in resource-limited countries.

Keywords: HIV, Lopinavir, Monotherapy, Lamivudine, Resistance, Thailand

Findings

There are many concerns raised regarding boosted protease inhibitor monotherapy in HIV treatment include this strategic treatment may not be as effective as other combined antiretroviral therapies (ART), high rate of low-level viremia and may lead to developing treatment failure, and a higher level of adherence is required than with the use of standard combined ART [1]. In addition, there is an important concern about the ability of monotherapy to penetrate viral reservoirs and prevent viral replication in sanctuary sites, such as genital tract and central nervous system. Studies evaluating ritonavir-boosted protease inhibitor monotherapy that derived from the western countries have been studied in three patient settings including initial treatment, induction-maintenance, and simplification monotherapy after patients have been virologically suppressed - all are in patients without treatment failure [2]. However, data regarding durability of this strategic treatment is still scanty, owing to supporting by only relatively short-term data. On the other hand, HIV is often resistant to most existing nucleoside reverse transcriptase inhibitors

* Correspondence: drweerawat@hotmail.com
1Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand
Full list of author information is available at the end of the article
total cholesterol was 165 ± 42 mg/dL and mean ± SD 55,800 (9,670-100,000) copies/mL. Mean ± SD baseline therefore, we conducted a prospective cohort study of ritonavir-boosted lopinavir monotherapy for the second-
line therapy in HIV-1 infected patients who failed anti-
retroviral regimens containing NRTIs and NNRTIs in such setting is often impossible. Therefore, we conducted a prospective cohort study of ritonavir-boosted lopinavir monotherapy for the second-line therapy in HIV-1 infected patients who failed anti-retroviral regimens containing NRTIs and NNRTIs as previously described [3]. In the present analysis, we con-
tinued the prospective cohort study with the objectives to determine the three-year virologic and immunologic responses, and lipid derangements.

The present study was designed as a prospective cohort study involving 40 HIV-1 infected patients who were diagnosed virologic failure at the Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Thailand. Virologic failure was defined as having viral load > 1,000 copies/mL after 6 months of treatment or a rebound of viral load to > 1,000 copies/mL in any duration after undetectable viral load. Discontinuation of lopinavir/ritonavir due to any reason was considered to be a treatment failure, i.e. plasma HIV-1 RNA > 1,000 copies/mL. Inclusion criteria were as follows: (1) HIV-1 infected patients > 18 years of age, (2) failed NNRTI-based ART with M184V, thymidine analogue mutations (TAMs) and NNRTI-associated mutations, and (3) had plasma HIV-1 RNA > 1,000 copies/mL. The patients were excluded if they had a history of exposure to protease inhibitor or receipt a medication that has drug-drug interactions with lopinavir or ritonavir. Rito-
navir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily. Ritonavir-boosted lopinavir soft gel formulation was changed to tablet formulation after 48 weeks of treatment. CD4 cell counts (flow cytometry), plasma HIV-1 RNA (Roche Amplicor, version 1.5), and lipid profiles were measured every 24 weeks. Medication adherence was assessed by pill count. All analyses were performed using SPSS software, version 15.0 (SPSS Inc., Chicago, IL, USA). This study was reviewed and approved by ethical committee for research in human subjects of the Department of Diseases Control, Ministry of Public Health and by the institutional review board.

As initial enrollment, there were 40 patients with a mean ± SD age of 37 ± 8 years and 70% were males. Median (IQR) baseline CD4 cell count was 123 (37-245) cells/mm³ and median (IQR) plasma HIV-1 RNA was 55,800 (9,670-100,000) copies/mL. Mean ± SD baseline total cholesterol was 165 ± 42 mg/dL and mean ± SD triglycerides was 172 ± 117 mg/dL. The frequencies of each thymidine analogue associated mutation (TAMs) were as follows: D67N, 17 (43%), T215FY, 16 (40%), M41L, 8 (20%), K65R, 6 (15%), L210W, 6 (15%), and K219Q, 2 (5%). M184V, Q151M and L74V were found in 40 (100%), 7 (18%) and 2 (5%), respectively. The pre-
vallence of patients with ≥1 major mutation conferring drug resistance to NNRTIs was 100%.

Figure 1 displayed the proportion of patients who had different stratum of plasma HIV-1 RNA at each follow-up visit by intend-to-treat analysis. At 144 weeks, 26 (65%) and 22 (56%) patients had achieved plasma HIV-1 RNA at < 400 and < 50 copies/mL, respectively. In as-
treated analysis, the corresponding rates were 26 of 28 (93%) and 22 of 28 (78%), respectively. Low-level viral rebound (HIV-1 RNA 50-400 copies/mL) was found in 6 patients, 6 (15%), 6 (15%), and 4 (10%) patients at week 48, 96 and week 144, respectively. Medians CD4 cell count at weeks 48, 96, and 144 were 351, 481, and 584 cells/mm³ and significantly changed from baseline (all, P < 0.05). Com-
pared measures to baseline values, there were increments of mean triglycerides at 48 weeks and 144 weeks from baseline (172 mg/dL vs. 338 mg/dL and 320 mg/dL, P < 0.05). LDL-cholesterol was not different (P > 0.05). No major protease resistance-associated mutations emerged after virologic failure. Three patients died over the study period. The attributed causes of death were cryptococcal meningitis (1 patient), sepsis (1), and hepatitis B virus-associated cirrhosis with fulminant hepatitis (1). Over the study period, 36, 32, and 28 patients continued to follow-up at weeks 48, 96, and 144 weeks.

A recent systematic review of lopinavir/ritonavir mono-
therapy demonstrated that overall response rate is not as effective as either continuing combined ART or giving ART at the beginning with relatively marginal significant magnitude, i.e. 95% confidence interval for this determina-
tion was 1.02 to 2.13 [2]. Of note, this strategic treatment appears most successful when patients are simplified from suppressive ART regimens for a period of time rather than starting monotherapy at the beginning [2]. Thus, this out-
come of lopinavir/ritonavir monotherapy among ART-
naïve patients may imply to our patients who experienced NRTI and NNRTI treatment but were protease inhibitor-
naïve and had high plasma viral load at the beginning. Our data indicate that the durability of ritonavir-boosted lopi-
avir monotherapy combined with recycled lamivudine regarding virologic suppression of patients who were fail-
ing NNRTI-based regimes with M184V, TAMs and NNRTI mutations is somewhat unfavorable. A recent pre-
liminary data of a randomized, controlled, trail demon-
strated that patients who failed NNRTI-based ART regimens and who were protease inhibitor-naïve, ritonava-
vir-boosted lopinavir monotherapy and ritonavir-boosted lopinavir combined with tenofovir/emtricitabine regimen
had similar proportions of patients with plasma HIV-1 RNA < 400 copies/mL, but not for < 50 copies/mL [4]. It is consistent with the present study showing a high proportion of patients with persistent viremia throughout the three-year follow-up period. One possible explanation is the lack of viral suppression in some compartments, such as genital secretion and cerebrospinal fluid [5]. Another explanation is an alternative pathway of protease inhibitor resistance facilitated by the absence of the NRTI drugs, different HIV subtypes influence on polymorphisms, and a non-adherence issue [6,7]. However, HIV resistant strains may be present at levels below the limit of detection of the test. One of our patients with unsuppressed viral load throughout the study period had compliance of less than 80%. Nonetheless, emerging protease resistance-associated mutation in patients who developed virologic failure with is rare in the previous reports [8,9]. In terms of immunologic outcome, the present study reveals that ritonavir-boosted lopinavir showed a great performance on the immunological response after three years of treatment.

Another concern is that the efficacy in reservoirs is still uncertain as aforementioned. Previous data showed that most of the patients had undetectable HIV-1 RNA in semen and vaginal compartment with ritonavir-boosted lopinavir monotherapy [10]. Nonetheless, Gutmann and colleagues showed that elevated viral load in cerebrospinal fluid and abnormal neurological symptoms were found in the patients who had virologic rebound after simplified maintenance with ritonavir-boosted lopinavir monotherapy [11]. Since the central nervous system penetration-effectiveness score is lower for boosted protease inhibitor monotherapy than for standard combined ART, it has been postulated that boosted protease inhibitor monotherapy might have a higher risk for virological failure in the central nervous system and it would contribute to further neurocognitive impairment [12,13].

This study provides evidence that long-term virologic control is possible in the patients failing NNRTI-based regimen and having limited options for active NRTI with receiving ritonavir-boosted lopinavir monotherapy and recycled lamivudine. However, this success is in a relatively small proportion of patients. Ritonavir-boosted lopinavir monotherapy should be prescribed with caution as a second-line option, especially in settings where close viral load monitoring is not available. As a consequence, more antiretroviral classes to assure the potency of the regimen are needed to be accessible in many resource-constrained settings. A further larger study is required to assess the risk and benefit of this proposed strategic treatment.

Acknowledgements
The authors wish to thank all the patients who participated in this study.

Funding statement
This study was supported by research grants from Bamrasnaradura Infectious Diseases Institute and Department of Disease Control, Ministry of Public Health, Thailand.

Transparency declarations
All authors declared no conflicts of interest.

Author details
1Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi 11000, Thailand. 2Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Authors’ contributions
WM participated in the design of the study, statistical analysis and draft the manuscript. ST, SN, SM, and SS participated in the design of the study and draft the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 21 December 2011 Accepted: 13 March 2012
Published: 13 March 2012

References
1. Perez-Valero I, Arribas JR: Protease inhibitor monotherapy. Curr Opin Infect Dis 2011, 24(1):7-11.
2. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA: HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009, 23(3):279-291.
3. Manosuthi W, Kientiburanakul S, Amornnimit W, Prasitsrisuk W, Thongyen S, Nirkamthang S, Runrugtham K, Sungkanupaph S: Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy
among HIV-infected patients who had NRTI and NNRTI failure. AIDS Res Ther 2009, 6:30.

4. Bunupuradah T, Chetchotisakd P, Munsakul W, Jirajariyavet J, Kantipong P, Prasithnikul W, Sangkanupraph S, Bowonwatanuwoong C, Kinrueaem V, Ruxrungtham K. Second-line LPV/r Monotherapy Was Inferior to TDF/3TC/LPV/r in Patients who Failed NNRTI Regimen: HIV STAR Study. Abstract of the 18th Conference on Retroviruses and Opportunistic Infections: Boston, February 27-March 1, 2011.

5. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klairkait T, Hoffmann M, Hirschel B. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007, 21(10):1309-1315.

6. Nijhuis M, van Maarseveen NM, Verheyen J, Boucher CA. Novel mechanisms of HIV protease inhibitor resistance. Curr Opin HIV AIDS 2008, 3(6):627-632.

7. Atkinson MJ, Petrozzino JJ. An Evidence-Based Review of Treatment-Related Determinants of Patients’ Nonadherence to HIV Medications. AIDS Patient Care STDs 2009, 23(11):903-914.

8. Arribas JR, Delgado R, Arranz A, Munoz R, Portilla J, Pasquau J, Perez-Elias MJ, Iriarren JA, Rubio R, Ocampo A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009, 51(2):147-152.

9. Nunes EP, Santini de Oliveira M, Mercon M, Zaplerver R, Faulhaber JC, Plotto JH, Ribeiro JE, Norton M, Schechter M. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials 2009, 10(6):368-374.

10. Yeh R, Hammill H, Fiscus S, Reski N, Miguel B, Kashuba A, Mayberry C, Nemerick J, Lipman B, Norton M, et al. Single Agent Therapy (SAT) with Lopinavir/ritonavir (LPV/rt) Controls HIV-1 Viral Replication in the Female Genital Tract, Abstract of the 11th European AIDS Conference (EACS): Madrid, October 24-27, 2007. P7.7/02.

11. Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, Cavasinini M, Yerby S, Vernazza PL. Randomized controlled study demonstrating failure of LPV/ritonavir monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010, 24(15):2347-2354.

12. Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR. Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother 2011, 66(3):1954-1962.

13. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011, 25(3):357-365.

doi:10.1186/1742-6405-9-8
Cite this article as: Manosuthi et al. Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure. AIDS Research and Therapy 2012, 9:8.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit